Oncology Highlights ASCO 2011 MULTIPLE MYELOMA
|
|
- Edgar Bailey
- 5 years ago
- Views:
Transcription
1 Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures None 1
2 Objectives 1. Provide an overview of novel agents presented at the annual meeting 2. Review health outcomes research in myeloma 3. Outline results regarding the use of bisphosphonates 4. Discuss the incidence of second primary malignancies Kyle, R. A. and Rajkumar S. V. Blood 28;111:
3 NEW DRUGS Carfilzomib and PX Carfilzomib is a selective tetrapeptide epoxyketone proteasome inhibitor that displays potent and sustained proteasome inhibition. The high degree of selectivity of carfilzomib may account for its improved tolerability profile: In early clinical studies, carfilzomib has not been associated with dose-limiting peripheral neuropathy (PN). PX is an ongoing multicenter, non-randomized, open-label, l single-arm phase 2 trial of single-agent carfilzomib in patients with R/R MM who have received 1 3 prior lines of therapy. K Stewart et al ASCO Abstract 826 3
4 Study Design and Treatment Bortezomib-naïve patients (N=129) were enrolled in 2 sequential dose cohorts. In Cohort 1, patients received carfilzomib 2 mg/m 2 IV on Days 1, 2, 8, 9, 15, and 16 every 28 days, for up to 12 cycles. In Cohort 2, patients received a stepped-up, dose-escalating regimen of carfilzomib 2 mg/m 2 for Cycle 1 followed by carfilzomib 27 mg/m 2 for all subsequent treatment cycles. Dexamethasone 4 mg was administered prior to carfilzomib in Cycle 1 only to ameliorate a potential first dose effect (including fever, chills, rigors, and dyspnea). Patients completing all 12 cycles were eligible to enroll in an extension study (PX-171-1). K Stewart et al ASCO Abstract 826 Significant Responses in BTZ-naïve Patients Significant response rates were observed in both cohorts Best response Cohort 1 2 mg/m 2 Cohort 2 2/27 mg/m 2 (N=127) (N=59) (N=68) n (%) n (%) CR 2 (3) () VGPR 8 (14) 18 (26) PR 15 (25) 17 (25) CBR= 59% MR 1 (17) 8 (12) SD 13 (22) 1 (15) ORR= 42% ORR= 51% PD 7 (12) 11 (16) NE 4 (7) 4 (6) CBR= 63% *Data cut-off date 9 February patients (3%) in Cohort 2 were excluded on the basis of missing baseline or post-baseline disease assessments. Responses confirmed by Independent Review Committee K Stewart et al ASCO Abstract 826 4
5 Substantial Duration of Response Observed for Cohorts 1 and 2 * *Data cut-off date 9 February 211 K Stewart et al ASCO Abstract 826 Similar Incidence and Severity of AEs Between Cohorts There were no discontinuations of treatment due to peripheral neuropathy. In no case were any toxicities iti (any grades) >2% higher h in Cohort 2 than in Cohort 1; in general they were either similar or lower cumulative toxicities has been observed in patients continuing on extended carfilzomib treatment (PX-171-1). K Stewart et al ASCO Abstract 826 5
6 Joe Commentary - Carlfilzomib Highly active proteasome inhibitor Huge benefit of lack of neuropathy Currently still given twice weekly IV Look for enhanced dosing schedules Going to FDA this summer Pomalidomide in Len Treated Patients Patient Characteristics J Mikhael et al ASCO Abstract 867 6
7 Response rate on Pomalidomide Despite Prior Treatment with Lenalidomide J Mikhael et al ASCO Abstract 867 Joe Commentary - Pomalidomide Highly active IMID Minimal neuropathy, likely less myelosuppression than lenalidomide Active in previously len treated patients, even when refractory in about 1/3 Going to phase 3 now, FDA 212? 7
8 Elotuzumab: Background 6 Elotuzumab is a humanized IgG1 mab targeting human CS1, a cell surface glycoprotein 12 5 CS1 is highly expressed on >95% of MM cells Lower expression on NK cells 3 Little to no expression on normal tissues 2 MoA of elotuzumab is primarily through NK cell-mediated ADCC 1 against myeloma cells 1,2 In a MM xenograft mouse model, antitumor activity of elotuzumab was enhanced by the addition of lenalidomide 4 Tumor volume (mm 3 ) Lenalidomide dosing* Elotuzumab or control IgG1 dosing Control IgG1 + DMSO Elotuzumab + DMSO Lenalidomide + control IgG Elotuzumab + lenalidomide Study day *Lenalidomide dosed at 5 mg/kg. Elotuzumab dosed at 1 mg/kg (below MED of 1 mg/kg). P Richardson et al ASCO Abstract Phase 1/2 Study Design Response Assessments Elotuzumab Dosing CYCLE 1 CYCLE 2 CYCLE 3 CYCLE 4 CYCLE N-1 5 CYCLE 6N Lenalidomide daily dose daily dose daily dose daily dose daily dose daily dose Cycle day Dexamethasone Phase 1* Dose escalation study of elotuzumab 5, 1, and 2 mg/kg IV in combination with: Lenalidomide 25 mg PO Low-dose dexamethasone 4 mg PO Phase 2 Pts randomized to elotuzumab 1 or 2 mg/kg IV as above Treatment continued until disease progression or unacceptable toxicity P Richardson et al ASCO Abstract
9 Phase 1/2 Study Design: Premedication Regimen Administered 3 6 minutes prior to elotuzumab infusion i Methylprednisolone 5 mg IV Diphenhydramine 25 5 mg PO or IV (or equivalent) Ranitidine 5 mg IV (or equivalent) Acetaminophen 65 1 mg PO A protocol amendment substituted methylprednisolone 5 mg IV with dexamethasone 8 mg IV (to align with phase 3 program) The premedication regimen was incorporated late in Phase 1 and consistently in Phase 2 P Richardson et al ASCO Abstract Phase 1/2 Key Eligibility Criteria Inclusion Relapsed and/or refractory MM with 1 3 prior therapies For Phase 1, 1 prior therapy Measurable disease by M protein Creatinine clearance 5 ml/min (Cockcroft-Gault method) Exclusion Thalidomide, bortezomib, or corticosteroids within 2 wks of the first dose Prior lenalidomide For Phase 1, within 6 wks of first elotuzumab dose P Richardson et al ASCO Abstract
10 Efficacy Best Confirmed Response (IMWG Criteria) Elotuzumab Elotuzumab 1 mg/kg 2 mg/kg Total Pts, n ORR ( PR), n (%) 36 (92) 44 (75) 8 (82) Stringent CR/CR, n (%) 5 (13) 4 (7) 9 (9) VGPR, n (%) 1 (26) 22 (37) 32 (33) PR, n (%) 21 (54) 18 (31) 39 (4) SD, n (%) 3 (8) 11 (19) 14 (14) PD, n (%) 2 (3) 2 (2) IMWG non-evaluable, n (%) 2 (3) 2 (2) P Richardson et al ASCO Abstract Conclusions Elotuzumab plus lenalidomide and low-dose dexamethasone has a high ORR in relapsed and relapsed/refractory MM 82% for all pts 42% achieved VGPR as best confirmed response Median PFS had not been reached after a median follow-up of 9.4 months The elotuzumab and lenalidomide combination was generally well tolerated Most common Grade 3/4 treatment-emergent AEs were neutropenia (19%), thrombocytopenia (17%), and lymphopenia (13%) Premedication regimen with IV corticosteroid decreased incidence and mitigated severity of infusion reactions All grade infusion reactions: 1% of pts without premedication vs 56% of pts with premedication Grade 3/4 infusion reactions:18% of pts without premedication vs 1% of pts with premedication P Richardson et al ASCO Abstract
11 Joe Commentary - Elotuzumab Theoretically excellent target for therapy First of many monoclonal Abs demonstrating activity Used in combination with novel agent, not monotherapy Will have to balance cost/toxicity with added benefit HEALTH OUTCOMES 11
12 Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience Most of the survival benefit is seen in <65 Analyzed 4 Phase 3 clinical trials (ASCT excluded) Three cohorts: A B C E Campagnaro et al ASCO Abstract 821 Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience E Campagnaro et al ASCO Abstract
13 Joe Commentary Health Outcomes Adds to various studies evaluating increased survival in myeloma At least doubling median OS! Greatest benefit seen in transplant eligible Await further work in elderly with use of novel agents MRC IX BISPHOSPHONATES 13
14 MRC Myeloma IX Analysis Schematic for ZOL vs CLO N = 1,96 Patients with newly diagnosed MM (stage I, II, III) R A N D O M I S A T I O N Zoledronic acid (4 mg a IV q 3-4 wk) + intensive or non-intensive chemotherapy (n = 981) Bisphosphonate treatment continued at least until disease progression Clodronate (1,6 mg/d PO) + intensive or non-intensive chemotherapy (n = 979) Endpoints (ZOL vs CLO) Primary: PFS, OS, and Response Secondary: SREs (time to first SRE, SRE incidence) and Safety SREs were defined as vertebral fractures, other fractures, spinal cord compression, and the requirement for radiation or surgery to bone lesions, or the appearance of new osteolytic bone lesions. G Morgan et al ASCO Abstract 81 MRC Myeloma IX Trial Status 1,96 evaluable patients 121 centres es Median follow-up 3.7 years ZOL 3.8 years CLO Median time on study drug, days Intensive: 396 ZOL; 49 CLO Non-intensive: 32 ZOL; 36 CLO Off-study Progressed or died: 59% ZOL; 64% CLO Stopped before progression: 24% ZOL; 19% CLO Abbreviations: CLO, clodronate; ZOL, zoledronic acid. G Morgan et al ASCO Abstract 81 14
15 MRC Myeloma IX ZOL Significantly SREs vs CLO in the Overall Population ZOL reduced the risk of SREs by 26% vs CLO (HR =.74; P =.4) % Patients with an SRE, CLO ZOL 35.3% 27.% Patients at risk, n ZOL CLO Time from randomisation, months Abbreviations: CLO, clodronate; HR, hazard ratio; SRE, skeletal-related event; ZOL, zoledronic acid. G Morgan et al ASCO Abstract 81 ZOL Significantly OS vs CLO in Patients With Bone Disease at Baseline (n = 1,35) ate distribution function estim OS, % patients Survival Clodronate (n = 682) 1 Zoledronic acid (n = 668) + Censored P =.17 HR:.82 (95% CI:.7,.96) ZOL CLO Survival, years since initial randomisation Abbreviations: CI, confidence interval; CLO, clodronate; HR, hazard ratio; ZOL, zoledronic acid. G Morgan et al ASCO Abstract 81 15
16 OS Was Similar for ZOL and CLO in Patients With No Bone Disease at Baseline (n = 578) estimate rvival distribution function e OS, % patients Sur Clodronate (n = 276) Zoledronic acid (n = 32) + Censored P =.469 HR:11(95%CI: , 14) 1.4) ZOL CLO Survival, years since initial randomisation Abbreviations: CI, confidence interval; CLO, clodronate; HR, hazard ratio; ZOL, zoledronic acid. G Morgan et al ASCO Abstract 81 MRC Myeloma IX ZOL Effects on SREs vs CLO by Survival Risk Status at Baseline High-risk disease a Low-risk disease b Cumulative incidence function for 1st SRE 5.5 Clodronate Zoledronic acid Cumulative incidence function for 1st SRE Clodronate Zoledronic acid Time, months Time, months ZOL CLO ZOL CLO G Morgan et al ASCO Abstract 81 16
17 MRC Myeloma IX SRE Risk Affected by Treatment, Haematologic Parameters, and SRE History Variable P Value Bisphosphonate (ZOL vs CLO) 72 <.1 C-TD vs CVAD (intensive) C-TDa vs MP (non-intensive) Serum calcium (high vs low) Serum creatinine (high vs low) Haemoglobin (high vs low) Platelets (high vs low) History of SRE (yes vs no) 2 86 <.1 Risk of on-study SRE Risk of on-study SRE F Davies et al ASCO Abstract 811 MRC Myeloma IX ZOL Continued to 1st SREs vs CLO After Completion of 1 Year tion Cumulative Incidence Funct.2 P =.12, log rank CLO.15.1 ZOL.5 1 year Patients, n Time Since 1-Year Post-randomisation, months ZOL CLO F Davies et al ASCO Abstract
18 MRC Myeloma IX ZOL Continued to 1st SREs vs CLO After Completion of 2 Years.2 Cumulative Incidence Func ction P =.12, log rank CLO ZOL 2 years Time Since 2-Years Post-randomisation, months Patients, n ZOL CLO F Davies et al ASCO Abstract 811 MRC Myeloma IX ZOL Maintained Trend to 1st SREs vs CLO Beyond 3 Years.2 Cumulative Incidence Func ction P =.112 log rank CLO ZOL 3 years Time Since 3-Years Post-randomisation, months Patients, n ZOL CLO Abbreviations: CLO, clodronate; SRE, skeletal-related event; ZOL, zoledronic acid. F Davies et al ASCO Abstract
19 Joe Commentary Bisphosphonates Intriguing data regarding possible survival benefit - sustained Most dramatically seen in pts with bone disease Caution regarding population of patients enhanced with thalidomide? Requires further corroboration with other studies, but swings pendulum back somewhat (ONJ) SECOND PRIMARY SECOND PRIMARY MALIGNANCIES 19
20 MM15: Progression-Free Survival 39 All Patients 6% Reduced Risk of Progression Years of Age 69% Reduced Risk of Progression Median PFS Median PFS 1 MPR-R MPR MP 31 months 14 months 13 months 1 MPR-R MPR MP Not reached 14.7 months 12.4 months Patients (%) 75 5 HR.395 P < HR.315 P <.1 25 HR.796 P = HR.675 P = Time (Months) Time (Months) Data cutoff : May 11, 21 A Palumbo et al ASCO Abstract 87 MM-15: SPM Analysis Methods 4 All MM-15 patient records were examined for SPM incidence in active treatment and long-term follow-up study phases Efficacy & PFS data cutoff: May 11, 21 (adjudicated assessment) Median of 25 months SPM & OS data cutoff: February 28, 211 Median of 3 months SPMs were identified by review of MedDRA terms under the Neoplasm System Organ Class SPM incidence rates per 1 person-years were calculated for hematologic and solid tumor malignancies MedDRA, Medical Dictionary for Regulatory Activities. A Palumbo et al ASCO Abstract 87 2
21 MM-15: SPM Data Cut-Off February 28, SPM, n (%) MPR-R (n = 15) MPR (n = 152) MP (n = 153) Total Invasive SPMs 12 (8.) 9 (5.9) 4 (2.6) Hematologic Malignancies 7 (4.7) 5 (3.3) 1 (.7) AML 4 (2.7) 2 (1.3) MDS to AML 1 (.7) 1 (.7) MDS 2 (1.3) 1 (.7) T-ALL 1 (.7) CMML 1(7) (.7) B-cell malignancy Solid tumors 5 (3.3) 4 (2.6) 3 (2.) Non-melanoma skin cancer 1 (.7) 4 (2.6) 5 (3.3) Median follow-up: 3 months A Palumbo et al ASCO Abstract 87 MM15: Risk for SPM vs PD/Death (Safety Population) 42 MPR-R MPR MP Patients (%) Time (Months) Time (Months) Time (Months) PD/Death Hematologic SPM Solid Tumor PD, progressive disease. A Palumbo et al ASCO Abstract 87 21
22 Retrospective Study Design 43 9 EMN experimental trials 2459 NDMM Patients CRD/CPR: n = 287 MPR: n = 685 ASCT-R maint: n = 484 VMPT: n = MP: n = 164 MPT: n = VMP: n = analyzed patients (with at least 1 year of follow-up) 661 excluded patients (diagnosed in the last year; after Mar 15, 21) Times of observation were censored on Mar 15, Palumbo A, et al. Blood. 28;112: Palumbo A, et al. J Clin Oncol. 21;28: Gay F, et al. Eur J Haematol. 21;85: A Palumbo et al ASCO Abstract 87 Incidence of Second Primary Malignancies in Normal Population 44 INCIDENCE Age Specific Rates (per 1 PY) Inc cidence Rate (per 1 PY Y) Years of Age Piedmont Cancer Registry, Italy, City of Turin, PY, person-year. A Palumbo et al ASCO Abstract 87 22
23 Second Primary Malignancies and MM Death Risk All patients Lenalidomide No Lenalidomide 45 Proportion of patients months months months Death Solid SPMs Hematologic SPMs A Palumbo et al ASCO Abstract 87 Comparison of Observed to Expected Rate of Second Primary Malignancies 46 SPMs observed in Italian patients SPMs expected from Italian Cancer Registry (age- and sex-adjusted) All Patients SPMs Observed a SPMs Expected b SIR 95% CI All patients Male Female Lenalidomide-treated patients SPMs SPMs Observed a Expected b SIR 95% CI Lenalidomide-treated patients Male Female CI, confidence interval; SIR, standardized incidence rate A Palumbo et al ASCO Abstract 87 23
24 Objectives & Methods 47 Assess and compare SPM incidence rates between the Len + Dex and PBO + Dex arms of MM-9/1 Compare the incidence rates of SPM in MM-9/1 to the incidence rate of invasive cancer occurring among similarly aged persons in the general population Incidence rates of SPMs per 1 person-years a were evaluated during active, double-blind treatment b and during long-term follow-up Median follow-up for survival: 48 months Data cut-off SPM analysis: February 211 M Dimopoulos et al ASCO Abstract 89 Incidence Rates for SPM During Active Treatment Phase (Safety Population) Len + Dex (N = 353) PBO + Dex (N = 35) SPM n (%) Incidence Rate 95% CI n (%) Incidence Rate 95% CI (per 1 PY) (per 1 PY) Invasive SPM 8 (2.3) , (.6).91.23, 3.66 Hematologic 2 (.6).42.11, 1.69 (.). -- AML (.). -- (.). -- MDS 2 (.6).43.11, 1.7 (.) B-cell malignancies (.). -- (.). -- Solid Tumors 6 (1.7) , (.6).91.23, 3.66 Non-Invasive SPM 11 (3.1) , (.6).91.23, 3.66 Non-melanoma skin cancer 11 (3.1) 2 (.6) TOTAL SPM 18 (5.1) a , (.9) a , 4.27 a 1 patient in each Len/Dex and PBP/Dex groups who had both a solid tumor and a non-melanoma skin cancer. These patients are counted only once in the total; The 2 Len + Dex pts who developed MDS both had hypoplastic bone marrow at study entry and had received prior ASCT with high-dose melphalan CI, confidence interval; MDS, myelodysplastic syndromes; PY, person-year; M Dimopoulos et al ASCO Abstract 89 24
25 Incidence Rates of Invasive SPM a During Treatment & Follow-up Phases 49 Double-blind phase Long-term follow-up only PBO + Dex (n = 35) SPM = 2 IR:.91 (95% CI ) 218 PY SPM = IR: 599 PY 817 PY total Len + Dex (n = 353) SPM = 8 IR: 1.71 (95% CI ) SPM = IR: 467 PY 419 PY 886 PY total Person-Years a Includes MDS and breast carcinoma in situ, excludes non-melanoma skin cancers. IR, incidence rate per 1 person-years; M Dimopoulos et al ASCO Abstract 89 SPM in RRMM: MM-9/1 Time to Invasive SPM (treatment period) 5 Patients (%) 5 25 Len + Dex PBO + Dex Hazard ratio: (95% CI ) P=.649 No. at Risk Time (months) Len + Dex PBO + Dex M Dimopoulos et al ASCO Abstract 89 25
26 Time to Progression or Second Primary Malignancy 51 Patients (%) 5 25 Treatment Median TTP/SPM P Value Len + Dex 12.4 months <.1 PBO + Dex 4.6 months Hazard ratio:.355 (95% CI ) Time (months) No. at Risk Len + Dex PBO + Dex An analysis of TTP including invasive SPMs as events demonstrated that treatment Len + Dex treatment maintains a favorable benefit-risk profile M Dimopoulos et al ASCO Abstract 89 Overall Survival Benefit from Len + Dex Including Data After Crossover Treatment Median OS P Value Len + Dex 38. months.45 PBO + Dex 31.6 months HR:.822 (95% CI ) Patients (%) Logrank P =.45 Wilcoxon P = Pepe-Fleming P = Overall Survival (months) Dimopoulos MA, et al. Leukemia. 29;23:
27 Long-term safety of lenalidomide in relapsed/refractory multiple myeloma patients: Analysis of pooled data 11 Celgene sponsored clinical trials At least 24 months of treatment SPM in per 1 person years Compared to SEER 3,839 patients LEN (n = 729; 19.1%) and LEN + dex (n = 3,83; 8.9%) Median LEN treatment duration 5 mos (range ) 313 (8.2%) pts receiving 24 mos of treatment B. G. Durie et al ASCO Abstract 886 Long-term safety of lenalidomide in relapsed/refractory multiple myeloma patients: Analysis of pooled data A total of 57 SPMs were identified 8 MDS 1 AML 2 B-cell malignancies 46 solid tumors Of these, 22/313 (7%) were in pts with 24 mos of LEN treatment (4 MDS, 1 AML, 17 solid tumors) Overall SPM IR was 2.35 for 24 mos of treatment Standardized incidence ratio (SIR) was.77 (CI ) IR for all invasive cancers reported from SEER (range per 1 PY for all persons ages 6-85+). B. G. Durie et al ASCO Abstract
28 Long-term safety of lenalidomide in relapsed/refractory multiple myeloma patients: Analysis of pooled data B. G. Durie et al ASCO Abstract 886 Joe Commentary Second Primary Malignancy Difficult to genuinely attribute increased risk due to lenalidomide Confounders include: Age of patients Use of alkylators Lack of detailed capture of all malignancies Need more careful data collection Place into context of known benefit of novel agent 28
29 Conclusions Survival in myeloma is improving, due to both novel agent use and stem cell transplant The most promising new agents include carlfilzomib and pomalidomide Bisphosphonates may improve survival in myeloma and remain effective in patients with bone disease Second primary malignancies in pts treated with lenalidomide may be increased but likely only marginally if at all 29
Treatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationStudy Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799
Phase I Study of Lorvotuzumab Mertansine (LM) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM) Jesus Berdeja 1, Francisco
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMyeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania
Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationHorizon Scanning Centre November Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436
Horizon Scanning Centre November 2012 Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436 This briefing is based on information available at the time of research and a limited literature
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationFuture Strategies For Refractory Myeloma. Marc S. Raab
Future Strategies For Refractory Myeloma Marc S. Raab Multiple Myeloma Clonal proliferation of malignant plasma cells. excess bone marrow plasma cells monoclonal protein osteolytic bone lesions renal disease
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More information